MXPA00006323A - Human papillomavirus vaccine - Google Patents

Abstract

The present invention provides Human Papilloma Virus (HPV) fusion proteins, linked to an immunological fusion partner that provides T helper epiptopes to the HPV antigen. Vaccine formulations are provided that are useful in the treatment or Prophylaxis of HPV induced tumours.

Description

VACCINE OF HUMAN PAPILLOMA VIRUSES DESCRIPTION OF THE INVENTION The present invention relates to vaccine compositions, comprising a fusion protein of E6 or / and E7 or E6, E7 of an HPV strain optionally linked to an immunological fusion pattern and formulated with an oligonucleotide containing CpG to vaccines that find utility in the treatment or prophylaxis of tumors or lesions induced by human papillomavirus. In particular, the present invention relates to vaccines comprising fusion proteins, comprising a protein or part of a protein that provides T-helper epitopes (such as protein D from Haemophilus influenzae B) and an antigen from a human papillomavirus (for example comprising an E6 or E7 protein of strain HPV 16 or 18 associated with cancer) that find use in the treatment or prophylaxis of tumors induced by human papilloma, wherein the vaccine is formulated with oligonucleotide containing CpG as an auxiliary. Papilloma viruses are small natural DNA tumor (7.9 kilobases, double chain structure), which is a highly specific species. More than 70 genotypes of individual human papillomavirus (HPV) have been described. Papilloma viruses are classified based on the species of origin (human, bovine, etc.) and the degree of genetic relationship with other papilloma viruses of the same species. Human papilloma viruses are generally specific to the skin or mucosal surfaces and have been broadly classified into "low" and "high" risk viruses. Low-risk HPVs usually cause benign injuries (warts or papillomas) that persist for several months or years. High-risk HPVs are associated with pre-neoplastic lesions and cancer. The strongest positive association between an HPV virus and human cancer is that which exists between HPV 16 and 18 and cervical carcinoma. More than 10 different types of HPV have also been found in cervical carcinomas including HPV 31 and HPV 33, although less frequently. Genital HPV infection in young sexually active women is common and many individuals can clarify the invention, or if the lesions develop, they return. Only a subgroup of infected individuals have lesions that progress to high-grade intraepithelial neoplasia and only a fraction of these progresses to invasive carcinoma. The cular events that lead to HPV infection have not been clearly established. The lack of an adequate in vitro system to propagate human papilloma virus has obstructed the progress towards better information regarding the viral cycle. At present, the different types of HPVs have been isolated and characterized with the help of cloning systems in bacteria and more recently in PCR amplification. The cular organization of the HPV genomes has been defined on a comparative basis with that of the well characterized type 1 bovine papilloma virus (BPV1). Although minor variations may occur, all genomes of HPVs described have at least 7 old genes, E1 to E7, and two late genes, L1 and L2. In addition, an upstream regulatory region hosts the regulatory sequences that appear to control most of the transcriptional events of the HPV genome. The E1 and E2 genes are involved in viral replication and transcriptional control, respectively, and tend to be disrupted by viral integration. E6 and E7 are involved in the viral transformation. E5 and has also been involved in this process. In HPVs involved in cervical carcinoma such as HPV 16 and 18, the oncogenic process starts after the integration of viral DNA. The integration results in the inactivation of genes encoding the capsid L1 and L2 proteins and the loss of the E2 repressor function leads to the deregulation of the E6 / E7 open reading frame by continuously installing the overexpression of the two early E6 proteins. and E7 that will lead to the gradual loss of normal cell differentiation and the development of carcinoma. E6 and E7 exceed the normal cell cycle by inactivating larger tumor suppressor proteins, p53 and pRB, the retinoblastoma gene product respectively. Carcinoma of the cervix is common in women and develops through a precancerous intermediate stage towards invasive carcinoma that frequently leads to death. The intermediate stages of the disease are known as cervical intraepithelial neoplasia and are classified as I to III in terms of increasing severity (CIN-1-lll). Clinically, an HPV infection of the female anogenital tract manifests as cervical flat condylomata, the hallmark of which is the coilocytosis that predominantly affects the superficial and intermediate cells of the cervical squamous epithelium. The coilocytes that are the consequence of a cytopathic effect of the virus appear as multinucleated cells with a transparent perinuclear ring. The epithelium is thick with abnormal keratinization responsible for the appearance of warts of the lesion. Such flat condylomata when positive for the 16 or 18 serotypes of HPV, are high risk factors for the evolution towards cervical intraepithelial neoplasia (CIN) and carcinoma in situ (CIS), which by themselves are considered as precursor lesions of carcinoma. of invasive cervix. The natural history of oncogenic HPV infection has three consecutive phases, mainly: (1) a phase of latent infection, (2) a phase of intranuclear viral replication with the product of complete virions, which corresponds to the occurrence of coilocytes. In this stage HPV is producing its total scale of proteins including E2, E5, E6, E7, L1 and L2, (3) a phase of viral integration in the cellular genome, which activates the beginning of malignant transformation and corresponds to CIN II and CIN III / CIS with progressive disappearance of coilocytes. In this stage, the expression of E2 is regulated in descending order, the expression of E6 and E7 is improved. Between CIN ll / lll and CIN 11 I / cervical carcinoma, the viral DNA changes from being episomal in the basal cells to the integration only of the E6 and E7 genes (tumor cells). 85% of all cervical carcinomas are squamous cell carcinoma very predominantly related to HPV 16 serotype. 105 and 5% are adenocarcinoma and adenosquamous cell carcinoma, respectively, and both types are predominantly related to serotype HPV 18 However, there are other oncogenic HPVs. International patent application No. WO 96/19496 describes variants of E6 and E7 proteins of human papilloma virus, particularly E6 / E7 fusion proteins with a deletion in both E6 and E7 proteins. These elimination fusion proteins are said to be immunogenic. Immunomodulatory oligonucleotides contain non-methylated CpG dinucleotides ("CpG") and are known (WO 96/02555, EP 468520). CpG is the abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it has been observed that the BCG DNA fraction can exert an antitumor effect. In other studies, it has been shown that synthetic oligonucleotides derived from BCG gene sequences are capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in the immunostimulation was then presented in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in Bacterial DNA, but they are rare in vertebrate DNA. It is currently believed that this difference in evolution allows the vertebrate immune system to detect the presence of bacterial DNA (as occurs during an infection), leading consequently to the stimulation of the immune system. The immunostimulant sequence as defined by Krieg: Purine-purine-CG-pyrimidine-pyrimidine and wherein the motif of CG is not methylated. In certain combinations of the 6 nucleotides, a palindromic sequence is present. Several of these motifs, either as repeats of a motif or a combination of different motifs, may be present in the same oligonucleotide. The presence of one or more of these oligonucleotides containing an immunostimulatory sequence can activate several immune subgroups, including natural killer cells (which produce interferon and have cytolytic activity) and macrophages (Wooldrige et al., Vol. 89 (No. 8) , 1977). Although other sequences containing non-methylated CpG not having this consensus sequence have now been shown to be immunomodulatory. The present invention provides compositions comprising a fusion protein of either E6 or / and E7 or an E6 / E7 optionally linked to an immunological fusion pattern having T cell epitopes, and aided with an oligonucleotide containing CpG immunomodulator. In a preferred form of the invention, the immunological fusion pattern is derived from protein D of Haemophilus influenza B. Preferably, the protein D derivative comprises approximately the first third of the protein, in particular approximately the first 100-110 amino acids N -terminals. Protein D can be lipidated (lipoprotein D). Other patterns of immune pattern include the non-structural protein of influenza virus, NS1 (hemagglutinin). Typically, 81 N-terminal amino acids are used, although different fragments may be used as long as they include T-helper epitopes. In another embodiment, the immune fusion pattern is the protein known as LYTA. Preferably, the C-terminal portion of the molecule is used. Lyta is derived from Streptococcus pneumoniae, which synthesizes an amidase of N-acetyl-L-alanine, LYTA amidase, (encoded by the lytA gene. {Gene, 43 (1986) p 265-272.}. specifically, it degrades certain bonds in the base structure of peptidoglycan.The C-terminal domain of the LYTA protein is responsible for the affinity to choline or some choline analogues such as DEAE.This property has been explored for the development of expression plasmids C-LYTA from C. coli useful for the expression of fusion proteins The purification of hybrid proteins containing the C-LYTA fragment at its amino terminus has been described. {Biotechnology: 10, (1992) p.795-798. As used herein, a preferred embodiment uses the repeat portion of the Lyta molecule found at the C-terminus starting at residue 178. A particularly preferred form incrates residues 188-305. p The invention in its preferred embodiment provides compositions comprising an immunomodulatory CpG oligonucleotide and a fusion protein comprising the protein D-E6 of HPV 16, protein D-E7 of HPV 16, protein D-E7 of HPV 18, protein D- E6 of HPV18 and protein D-E6-E7 of both HPV 16 and 18. The part of protein D preferably comprises the first third of protein D. It will be appreciated that other E6 and E7 proteins can be used for other HPV subtypes . The proteins used in the present invention are preferably expressed in E. coli. In a preferred embodiment, the proteins are expressed with a histidine end comprising between 5 and 9 and preferably 6 histidine residues. These are advantageous to help purification. The E7 protein may, in one embodiment, prefer to carry one or more mutations at the binding site for rb (retinoblastoma gene product) and thus eliminate any potential transformation capacity. Preferred mutations for HPV 16 E7 involve replacing Cys2 with glycine, or glutamic acid26 with glutamine. In a preferred embodiment, the E7 protein contains both mutations. Preferred mutations for HPV 18 E7 involve replacing Cys27 with glycine and / or glutamic acid29 with glutamine. Again, preferably, both mutations are present. Individual mutations or doubles can also be introduced into the p53 region of E6 to eliminate any potential transformation abilities. In yet another embodiment of the invention, an HPV E6-E7 fusion protein linked to an immunological fusion standard and a CpG immunomodulatory oligonucleotide is provided. The vaccine of the present invention preferentially induces a TH1 immune response. Two main types of T helper have been characterized, TH1 and TH2, which differ in the type of secreting cytokines. These cytokines can be considered as the driving force behind the development of two different types of immune response: the TH1 type of immune response is associated with cell-mediated effector mechanisms such as the production of INF-? and the IL-2 cytokines by T lymphocytes. INF-? which in turn can activate other cells and induce them to secrete other important cytokines and mediators (NK cells activated by INF-? produce IL12, NK cells activated by IL2 are transformed to a lymphokine-activated annihilating cell (LAK), INF-activated macrophages - secrete inflammatory mediators such as TNFa, IL, IL6 and release nitric oxide, IL2 can provide help for the differentiation of restricted cytotoxic T lymphocytes, of the haploid type, of specific antigen (CTL). Th1 immune response is also associated with the generation of IgG2 isotype antibodies (IgG2a in Balb / ce mice IgG2b in C57BL / 6 mice) .The Th2 type of immune response is associated with a humoral immune response to the antigen. cytokines of type IL4, IL5, IL6, IL10 and through the generation of a broad scale of immunoglobulin isotypes including in mice lgG1, IgA, and IgM In humans, the distinction between Th1-type immune responses and Th2 is not absolute. An individual will withstand an immune response that is predominantly Th1 or predominantly Th2. However, it is usually convenient to consider cytokine families in terms such as those described in murine CD4 + ve T cell clones by Coffman (Mosmann, TR and Coffman RL (1980) TH1 and TH2 cells: different patterns of limphokine secretion lead to different functional properties, Annual Review of Immunology, 7, pp. 145-173). In the human type TH1 response is also associated with the presence of cytokine (IFNg and IL2) finally with the presence of isotypes CT1 and IgG2 in mice that correspond to IgG1 type antibodies. This type 1 phenotype is of particular importance to protect against intracellular viral and bacterial infections, as well as in the treatment of cancer. To produce the proteins used in the invention through recombinant techniques, an expression strategy involving E7, E6 or E6 / E7 can be used, fusion to the 1/3-N-terminal portion of Haemophilus protein D Influenzae B, an immunological fusion pattern providing T-cell helper epitopes. One end of affinity polyhistidine was engineered into the carboxy terminus of the fusion protein allowing for simplified purification. Said recombinant antigen is overexpressed in E. coli as an insoluble protein. The proteins of the invention can be co-expressed with thioredoxin in trans (TIT). Co-expression of thioredoxin in trans against cis is preferred to keep the antigen free of thioredoxin without the need for protease. The co-expression of thioredoxin facilitates the solubilization of the proteins of the invention. The co-expression of thioredoxin also has an important impact on the production of protein purification, on the solubility and quality of the purified protein. Replicable expression vectors can be prepared according to the invention, by dividing a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together, with the linear segment they encode the desired product, such as the DNA polymer encoding the protein of the invention or its derivative, under ligation conditions. In this way, the DNA polymer can be preformed or formed during construction of the vector, as desired. The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic, but preferably is E. coli. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant virus. The preparation of the replicable expression vector can be carried out conventionally with enzymes suitable for restriction, polymerization and ligation of the DNA, through methods described in, for example, Maniatis et al., Cited above. The recombinant host cell is prepared, according to the invention, by transforming a host cell with a replicable expression vector of the invention under transformation conditions. Suitable transformation conditions are conventional and are described in, for example, Maniatis et al., Cited above, or "DNA Cloning" Vol. II, DM Glover ed., IRL Press Ltd, 1985. The selection of transformation conditions is determined by the host cell. In this way, a bacterial host such as E. coli can be treated with a CaCl 2 solution (Cohen et al., Proc. Nat. Acad. Sci., 1973, 69. 2110), or with a solution comprising a mixture of RbCl. , MnCl2, potassium acetate and glycerol, and then with 3- [N-morpholino] -propane-sulphonic acid, RbCI and glycerol. The mammalian cells in culture can be transformed through calcium co-precipitation of the DNA vector on the cell. The invention also extends to a host cell transformed with a replicable expression vector of the invention. The culture of the transformed host cell under conditions that allow the expression of the DNA polymer is conventionally performed, as described in, for example, Maniatis et al., and "DNA Cloning", cited above. In this way, preferably the cell is supplied with nutrients and cultured at a temperature below 50 ° C. The product is recovered by conventional methods according to the host cell. In this way, when the host cell is bacterial, such as E. coli, it can be used physically, chemically or enzymatically and the protein product isolated from the resulting lysate. When the host cell is a mammal, the product can generally be isolated from the nutrient medium or from cell-free extracts. Conventional protein isolation techniques include selective precipitation, adsorption chromatography and affinity chromatography including a monoclonal antibody affinity column.

When the proteins of the present invention are expressed with a histidine end (His tag), the proteins can be easily purified through affinity chromatography using an ion metal ion chromatography column (IMAC). A second chromatographic step, such as Q-sepharose, can be used either before or after the IMAC column to produce a highly purified protein. If the immunological fusion pattern is C-LYTA, then it is possible to exploit the affinity of C-LYTA for choline and / or DEAE to purify this product. Products containing both C-LYTA and its label can be easily and efficiently purified in a two step process, involving differential affinity chromatography. One step involves the affinity of the His tag to IMAC columns, the other involves the affinity of the C-terminal domain of LYTA for choline or DEAE. A preferred vaccine composition comprises at least the HPV 16 D-E6 protein or a derivative thereof together with the HPV 16 E7 protein D. Alternatively, E6 and E7 may be presented in a single molecule, preferably a D protein. E6 / E7 fusion. Said vaccine may optionally contain either or both HPV 18 E6 and E7 proteins, preferably in the form of a D-E6 protein or D-E7 protein, as a fusion protein, or protein E6 / E7 fusion protein. The vaccines of the present invention may contain other HPV 16 or 18 HPV antigens. In particular, the vaccine may contain L1 or L2 antigen monomers. Alternatively, said L1 or L2 antigens may be present together as a virus as a particle or the L1 alone protein may be present as a virus as a particle or capser structure. Said antigens, virus-like particles and capsomer are known per se. See, for example, WO 94/00152, WO 94/20137, WO 94/05792, and WO 93/02184. In addition, previous proteins such as E2 or preferably E5, for example, may be included. The vaccine of the present invention may further comprise antigens from other strains of HPV, preferably from strains HPV 6, 11, 31 or 33. The preparation of the vaccine is generally described in Vaccine Design-The Subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology, Vol. 6 Plenum Press 1995. Encapsulation within the liposome is described by Fullerton, US Patent 4,235,877. Preferred oligonucleotides preferably contain two or more CpG motifs separated by two or more nucleotides. The oligonucleotides of the present invention are typically deoxynucleotides. In a preferred embodiment, the internucleotide in the oligonucleotide is phosphorodithioate, or most preferably a phosphorothioate linkage, although the phosphodiester and other internucleotide linkages are within the scope of the invention including oligonucleotides with mixed internucleotide linkages. Preferred oligonucleotides have the following sequences: the sequences preferably contain all internucleotide linkages modified with phosphorothioate. OLIGO 1: TCC ATG ACG TTC CTG ACG TT OLIGO 2: TCT CCC AGC GTG CGC CAT OLIGO 3: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG The CpG oligonucleotides used in the present invention can be synthesized by any known method in the technique (e.g., EP 468520). Conveniently, said oligonucleotides can be synthesized using an automatic synthesizer. Methods for producing phosphorothioate or phosphorodithioate oligonucleotides are described in U.S. Patent No. 5,666,153, U.A. Patent 5,278,302 and WO 95/26204. The invention will now be described with reference to the following examples.

EXAMPLE I Construction of an expression fusion protein of E. coli strain D1 / 3-E7-HIS (HPV16) 1) Construction of the expression plasmid a) The plasmid pMG MCS prot D1 / 3 (= pRIT14589) is a derivative of pMG81 (described in British Patent Application No. 951 3261.9 published as WO 97/01640) wherein codons 4-81 of the NS1 coding region of Influenza were replaced at codons corresponding to residues 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenza, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. P. 119-125).

The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one C-terminal histidine terminus. This plasmid was used to express the fusion protein D1 / 3-E7.His. b) HPV 16 HPV genomic E6 and E7 sequences (see Dorf et al., Virology 1985, 145, pages 181-185) were amplified from the HPV 16 full length genome cloned into pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papíllomaviruses- D69120 -Heidelberg) and were subcloned into pUC19 to give TCA301 (= pRIT14462).

Construction of plasmid TCA308 (= pRIT4501): a plasmid expressing the D1 / 3-E7-His fusion protein. The nucleotide sequences corresponding to amino acids 1? 98 of the E7 protein were amplified from pRIT14462. During the polymerase chain reaction, the Ncol and Spel restriction sites were generated at the 5 'and 3' ends of the E7 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give the plasmid TCA308 (= pRIT14501). The insert was sequenced to verify that no modification was generated by the polymerase chain reaction. The sequence for the D1 / 3-E7-His fusion protein (HPV 16) is described in the sequence of ID No. 1 and the coding sequence in ID No. 2) Transformation of the AR58 strain The plasmid pRIT14501 was introduced in E. coli AR58 (Mott et al., 1985, Proc. Nati. Acad. Sci., 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3) Growth and induction of the bacterial strain-expression of Prot-D1 / 3-E7-His. The AR58 cells transformed with the plasmid pRIT14501 were grown in 100 ml of LB medium supplemented with 50 μg / ml kanamycin at 30 ° C. During the logarithmic phase of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and activate the synthesis of the D1 / 3-E7-His protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C.

EXAMPLE II Construction of an E. coli strain expressing the D1 / 3-E6-his / HPV16 fusion protein 1) Construction of the expression plasmid a) The plasmid pMG MCS prot DI / 3 (= pRIT14589) is a derivative of pMG81 ( described in WO 97/01640) wherein codons 4-81 of the NS1 coding region of Influenza were replaced at codons corresponding to residues 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p 119-125). The sequence of Prot-D1 / 3 was followed through a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). This plasmid was used to express the D1 / 3-E6-his fusion protein. b) HPV 16 genomic HPV E6 and E7 sequences (see Dorf et al., Virology 1985, 145, pages 181-185) were amplified from the HPV 16 full-length genome cloned into pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papillomaviruses-c) D69120 -Heidelberg) and were subcloned into pUC19 to give TCA 301 (= pRIT14462).

Construction of plasmid TCA 307 (= pRIT14497): a plasmid expressing the fusion protein D1 / 3-E6-His / HPV16 The nucleotide sequences corresponding to amino acid 1? 151 of the E6 protein were amplified from pRIT14462.

During the polymerase chain reaction, the Ncol and Spel restriction sites were generated at the 5 'and 3' ends of the E6 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give plasmid TCA 307 ( = pRIT14497). The insert was sequenced to verify that no modification was generated during the polymerase chain reaction. The protein and coding sequence for the D1 / 3-E6-His fusion protein is described in the sequence of ID No. 3 and 4. 2) Transformation of strain AR58 Plasmid pRIT14497 was introduced into E. coli AR58 (Mott et al., 1985, Proc. Nati. Acad. Sci., 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3) Growth and induction of the bacterial strain-expression of Prot-D1 / 3-E6-His. AR58 cells transformed with the plasmid pRIT14497 were developed in 100 ml of LB medium supplemented with 50 μg / ml kanamycin at 30 ° C. During the logarithmic phase of the developed bacteria were they displaced at 39 ° C to inactivate the repressor? and activate the synthesis of the D1 / 3-E6-His protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4) Characterization of the fusion protein DI / 3-E6-his (HPV 16) Preparation of extracts Frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. Analysis on SDS-polyacrylamide gels stained with Coomassie and Western stains After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis Western staining.

A band greater than approximately 32 kDa, located in the pellet fraction, was visualized through Coomassie stained gels and identified in Western stains through rabbit polyclonal anti-protein-D and through the Ni-NTA conjugate coupled to phosphatase calf intestinal alkaline (Qiagen cat No. 34510), which detects the accessible histidine end. The level of expression represents approximately 5% of the total protein. 5) Co-expression with thioredoxin In an analogous manner the expression of prot D 1/3 E7 His from HPV 18 (Example IX), an E. coli strain AR 58 was transformed with a plasmid encoding thioredoxin and protein D 1/3 E7 His (HPV 16).

EXAMPLE III Construction of an E. coli strain expressing the D1 / 3-E6E7-his / HPV16 fusion protein 1) Construction of the expression plasmid a) Plasmid pMG MCS prot DI / 3 (= pRIT14589) is a derivative of pMG81 (described above) where codons 4-81 of the NS1 coding region of Influenza were replaced by the codons corresponding to the 20? - Thr 127 residues of the mature D protein of strain 772 of Haemophilus Influenzae, biot? 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p.129-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). This plasmid was used to express the D1 / 3-E6-his fusion protein. b) HPV 16 genomic HPV E6 and E7 sequences (see Dorf et al., Virology 1985, 145, pages 181-185) were amplified from the full length HPV 16 genome cloned into pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papillomaviruses) -D69120 -Heidelberg) and were subcloned into pUC19 to give TCA301 (= pRIT14462). c) The coding sequences of Ea and E7 in TCA301 (= pRIT14462) were modified with an adapter of synthetic oligonucleotides (inserted between the sites Afl III and Nsi I), introducing a deletion of 5 nucleotides between the E6 and E7 genes to remove the E6 retention codon and create E6 and E7 coding sequences fused in the TCA309 plasmid (= pRIT 14556) Construction of the TCA 311 plasmid (= pRIT14512): a plasmid expressing the D1 / 3-E6E7-His fusion protein / HPV16 The nucleotide sequences corresponding to amino acids 1-249 of the fused E6E7 protein were amplified from pRIT14556. During the polymerase chain reaction, the Ncol and Spel restriction sites were generated at the 5 'and 3' ends of the fused E6E7 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give the plasmid TCA311 (= pRIT14512). The insert was sequenced to verify that no modifications were generated during the polymerase chain reaction. The protein and coding sequence for the fusion protein D E6 / E7 1/3-His is described in the sequence of ID No. 5 and 6. 2) Transformation of the strain AR58 The plasmid pRIT14512 was introduced in E. coli AR58 (Mott and others, 1985, Proc. Nati Acad. Sci., 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3) Growth and induction of the bacterial strain-expression of Prot-D1 / 3-E6E7-His. The AR58 cells transformed with the plasmid pRIT14512 were grown in 100 ml of LB medium supplemented with 50 μg / ml kanamycin at 30 ° C. During the logarithmic phase of the developed bacteria were they displaced at 39 ° C to inactivate the repressor? and activate the synthesis of the D1 / 3-E6E7-His protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4) Characterization of the DI / 3-E6E7-his fusion protein. Frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm2 (three steps). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western grafting. A band greater than approximately 40 kDa, located in the pellet fraction, was visualized through Coomassie stained gels and identified in Western stains through rabbit polyclonal anti-protein-D and through the Ni-NTA conjugate coupled to phosphatase intestinal alkaline (Qiagen cat. No. 34510), which detects the accessible histidine end. The level of expression represents approximately 1% of the total protein.

EXAMPLE IV In an analogous manner, the fusion protein of Lipo D 1/3 and E6-E7 of HPV16 was expressed in E. coli in the presence of thioredoxin. The N-terminus of the pre-protein (388 aa) contains MDP residues followed by 16 amino acids of the lipoprotein D signal peptide (from Haemophilus Influenzae), which was divided live to give the mature protein (370 aa) . The portion of lipoprotein aa 1 to 127) was followed through the fusion proteins E6 and E7. The C-terminus of the protein was lengthened by TSGHHHHHH.

EXAMPLE V Construction of E. coli strain B1002 expressing fusion ProtD1 / 3-E7. HPV16 of type (cys24-> gly, glu26-> gnm) mutated 1) Construction of the expression plasmid Starting material: a) Plasmid pRIT 14501 (= TCA 308), which codes for protein ProtDI / 3- E7-His fusion, b) Plasmid LITMUS 28 (New England Niolabs cat No. 306-28), a cloning vector of pUC derivative. c) Plasmid pMG MCS Prot DI / 3 (pRIT14589) is a derivative of pMG81 (described above) where codons 4-81 of the NS1 coding region of Influenza were replaced by codons corresponding to residues 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p 119-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). Construction of the pásmid pRIT 14773 (= TCA347): a plasmid expressing the mutated D1 / 3-E7 fusion protein (cys24 > gly, glu26 > gln) with the end of His. The Ncol-Xbal fragment from pRIT 14501 (= TCA 308), carrying the E7 gene coding sequence from HPV 16, elongated with a His end, was subcloned into a Litmus 28 intermediate vector useful for mutagenesis to give pRIT 14909 (= TCA337). Double mutations cys24-- > gly (Edmonds and Vousden, J. Rirology 63: 2650 (1989) and glu26-> gn (Pheips et al., J. Virology 66: 2418-27 (1992)) to damage the binding to the antioncogene product of the retinoblastoma gene (pRB) The introduction of mutations in the E7 gene was carried out with the team Quick Change Site directed Mutagenesis (Stratagene Cat No. 200518) to give the plasmid pRIT 14681 (= TCA343) .After verification of the presence of mutations and integrity of the complete E7 gene by sequencing, the mutated E7 gene was introduced into the vector pRIT 14589 (= pMG MCS ProtD1 / 3) to give the plasmid pRIT 14733 (= TCA347) as the protein and coding sequence. mutated D1 / 3-E7 fusion protein (cys24 -> gly, glu26 -> gln) -His is described in sequence ID No. 7 and 8. 2) Construction of strain B1002 expressing ProtD1 / 3- E7 mutated (cys 24 -> gly, glu26 -> gln) His / HPV16. Plasmid pRIT 14733 was introduced to E. Coli AR58 (Mott et al. , 1985, Proc. Nati. Acad. Sci., 82:88), a lysogen? defective containing a thermosensitive promoter repressor? pL, to give strain B1002, selected transformants resistant to kanamycin. 3) Growth and induction of bacteria strain B1002-expression of ProtD1 / 3-E7 mutated with (cys 24 -> gly, glu26 -> gln) His / HPV16. The Ar58 cells transformed with the plasmid pRIT 14733 (strain B1002) were grown at 30 ° C in 100 ml of the LB medium supplemented with 50 μg / ml kanamycin. During the logarithmic phase of growth bacteria that were displaced at 39 ° C to inactivate the repressor? and activate the synthesis of -His / HPV16 mutated with ProtD1 / 3-E7. Incubation at 39 ° C was continued for 4 hours. The bacteria were pelleted and stored at -20 ° C. 4) Characterization of ProtD1 / 3-E7 mut (cys 24 -> gly, glu26 -> gln) -His fusion, type HPV16. Frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16, 000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, the aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western grafting. A band greater than approximately 37 kDa, located in the pellet fraction, was visualized through gels stained with Coomassie and identified in Western stains through polyclonal anti-D protein of 22 J 70 through monoclonal E7 / HPV 16 of Zymed and by Ni-NTA as a conjugate coupled to calf intestinal alkaline phosphatase (Qiagen cat. No. 34510), which detects the accessible histidine endpoint. The level of expression represents approximately 3 to 5% of the total protein. The B1002 cells were separated from the culture broth and centrifuged. The concentrated B1002 cells were stored at -65 ° C.

EXAMPLE VI Construction of an E. coli strain expressing clyta-E6-his (HPV 16) fusion. 1. Construction of the expression plasmid. a) The plasmid pRIT14497 (= TCA307), which codes for the fusion protein ProtD1 / 3-E6-His / HPV16. b) The plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA from Streptococcus Pneumoniae. Lyta was derived from Streptococcus Pneumoniae, which synthesizes an amidase of N-acetyl-L-alanine, LYTA amidase, (encoded by the lytA gene. {Gene, 43 (1986) p 265-272.}. specifically degrades certain bonds in the base structure of peptidoglycan.The C-terminal domain of the LYTA protein is responsible for the affinity to choline or some choline analogs such as DEAE 1.b. Construction of the plasmid pRIT14634 (= TCA332) : a plasmid expressing clyta-E6-His (fusion HPV16) The first step was the purification of the large Ncol-Aflll restriction fragment from the plasmid pRIT14497 and the purification of the small Aflll-Afllll restriction fragment from PRIT14661 b) The second step was to link the clyta sequences to the E7-His sequences (Ncol and Afllll are compatible restriction sites) that gave rise to the plasmid pRIT14634 (= TCA332), which codes for the fusion protein clyta-E6-His under the control l of the pL promoter. The protein and coding sequence for the clyta-E6-His fusion protein is described in sequence ID No. 9 and 10. Transformation of strain AR58 Plasmid pRIT14634 was introduced into E. coli AR58 (Mott et al., 1985 , Proc. Nati, Acad. Sci. 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. Growth and induction of the bacterial strain-expression of clyta-E6-His AR58 cells transformed with the plasmid pRIT14634 were developed in 100 ml of the LB medium supplemented with 50 μg / ml of kanamycin at 30 ° C. During the logarithmic phase of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and activate the synthesis of the protein clyta-E6-his. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4. Characterization of clyta-E6-his fusion The frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western grafting.

A band greater than approximately 33 kDa, located in the pellet fraction, was visualized through gels stained with Coomassie and identified in Western stains through rabbit polyclonal anti-clyta antibodies and through the Ni-NTA conjugate coupled to the phosphatase. calf intestinal alkaline (Qiagen cat No. 34510), which detects the accessible histidine end. The level of expression represents approximately 3% of the total protein.

EXAMPLE VII Construction of an E. coli strain expressing clyta-E7-his (HPV 16) fusion 1. Construction of expression plasmid 1.a Starting materials a) Plasmid pRIT14510 (= TCA308), which codes for fusion ProtD1 / 3- E7His / HPV16. b) The plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA from Streptococcus Pneumoniae. 1 B. Construction of the plasmid pRIT14636 (= TCA330): a plasmid expressing fusion clyta-E7-H is / H PV16 a) The first step was the purification of the large Ncol-Aflll restriction fragment from the plasmid pRIT14501 and the purification of the fragment restriction Aflll-Afllll small from pRIT14661. b) The second step was to link the clyta sequences to the E7-His sequences (Ncol and Afllll are compatible restriction sites) that gave rise to the plasmid pRIT14626 (= TCA330), which codes for the clyta-E7-His fusion protein under the control of the pL promoter. The protein and coding sequence for the clyta-E7-His fusion protein is described in sequence ID No. 11 and 12. 2. Transformation of strain AR58 Plasmid pRIT14626 was introduced into E. coli AR58 (Mott et al. , 1985, Proc. Nati, Acad. Sci. 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3. Growth and Induction of the Bacterial Strain-Clyta-E7-His Expression AR58 cells transformed with the plasmid pRTI14626 were grown in 100 ml of the LB medium supplemented with 50 μg / ml kanamycin at 30 ° C. During the logarithmic phase of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and activate the synthesis of the protein clyta-E7-his. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4. Characterization of fusion clyta-E7-his The frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western grafting. A band greater than approximately 35 kDa, located in the pellet fraction, was visualized through Coomassie stained gels and identified in Western stains through rabbit polyclonal anti-clyta antibodies and through the Ni-NTA conjugate coupled to the phosphatase. calf intestinal alkaline (Qiagen cat No. 34510), which detects the accessible histidine end. The level of expression represents approximately 5% of the total protein.

EXAMPLE VIII Construction of an E. coli strain expressing fusion clyta-E6E7 his (HPV 16) 1- Construction of expression plasmid 1.a Starting materials a) Plasmid pRIT14512 (= TCA311), encoding ProtD1 / 3- E6E7-HIS / HPV16 fusion. b) The plasmid pRIT14661 (= DVA2), an intermediate vector containing the coding sequence for the 117 C-terminal codons of LytA from Streptococcus Pneumoniae. 1 B. Construction of the plasmid pRIT14629 (= TCA331): a plasmid expressing fusion clyta-E6E7-His / HPV16 a) The first step was the purification of the large Ncol-Aflll restriction fragment from the plasmid pRIT14512 and the purification of the restriction fragment Aflll-Afllll small from pRIT14661. b) The second step was to bind the clyta sequences to the E7-His sequences (Ncoi and Afllll are compatible restriction sites) that gave rise to the plasmid pRIT14629 (= TCA331), which codes for the clyta-E6E7-His fusion protein under the control of the pL promoter. The protein and coding sequence for the clyta-E6E7-His fusion protein is sequence ID No. 13 and 14. 2. Transformation of strain AR58 Plasmid pRIT14629 was introduced into E. coli AR58 (Mott et al., 1985 , Proc. Nati, Acad. Sci. 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3. Growth and induction of the bacterial strain-expression of clyta-E6E7-His The AR58 cells transformed with the plasmid pRTI14629 were developed in 100 ml of the LB medium supplemented with 50 μg / ml of kanamycin at 30 ° C. During the logarithmic phase of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and to activate the synthesis of the clyta-E6E7-his protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4. Characterization of clyta-E6E7-his fusion The frozen cells were thawed and resuspended in 10 ml of the PBS pH regulator. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western grafting. A band greater than approximately 48 kDa, located in the pellet fraction, was visualized through Coomassie stained gels and identified in Western stains through polyclonal rabbit anti-clyta antibodies and through the Ni-NTA conjugate coupled to the phosphatase. calf intestinal alkaline (Qiagen cat No. 34510), which detects the accessible histidine end. The level of expression represents approximately 1% of the total protein.

EXAMPLE IX Prot D1 / 3E7 his (HPV 18) (E. Coli B1011) Protein D1 / 3 E7 his HPV with thioredoxin in Trans (E. coli B1012) 1. Construction of expression plasmids 1.a Construction of plasmid TCA316 (= pRIT 14532), a plasmid expressing the fusion protein D1 / 3-E7-His / HPV18 Starting materials a) Plasmid pMG MCS prot DI / 3 (= pRIT14589) is a derivative of pMG81 (described in British Patent Application No. 951 3261.9 published as WO 97/01640) wherein codons 4-81 of the NS1 coding region of Influenza were replaced at corresponding codons. to waste 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. P. 119-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). This plasmid was used to express the D1 / 3-E7-His fusion protein. b) Prototype HPV 18 HPV genomic E6 and E7 sequences (Colé et al., J. Mol. Biol. (1987) 193, 599-608) were identified from HPV 16 of full-length genome cloned in pBR322 ( obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papillomaviruses-D69120 -Heidelberg) and were subcloned into pUC19 to give TCA302 (= pRIT14467). Construction of plasmid TCA316 (= pRIT14532) The nucleotide sequences corresponding to amino acids 1? 105 of the E7 protein were amplified from pRIT14467. During the polymerase chain reaction, the Ncol and Spel restron sites were generated at the 5 'and 3' ends of the E7 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give the plasmid TCA316 (= pRIT14532). The insert was sequenced and a modification was identified against the prototype sequence E7 / HPV18 in the E7 gel (nucleotide 128 G> A) generating a substitution of a lysine through a glutamic acid (aa 43 in E7, position a56 in the fusion protein). The protein to the coding sequence of the fusion protein D1 / 3-E7-His / HPV 18 are set in sequence ID No. 15 and ID No. 16. 1.b Construction of the plasmid TCA313 (= pRIT14523): a plasmid expressing thioredoxin Starting materials a) Plasmid pBBR1MCS4 (Antoine R. and C. Locht, Mol Microbiol 1992.6,1785-1799, MEKovach et al., Biotechniques 16, (5), 800-802), which is compatible with plasmids containing ColE1 or P15a origins of replication. b) Plasmid pMG42 (described in WO93 / 04174) containing the pL promoter sequence of phage Lambda. c) The pTRX plasmid (Invitrogen, Thiofusion K350-01 kit) carrying the coding sequence for thioredoxin followed by the transcription terminator AspA. Construction of Plasmid TCA313 (= pRIT4523) The EcoRI-Ndel fragment from pMG42, carrying the pL promoter and the Ndel-Hindlll fragment from pTRX, carrying the thioredoxin coding sequence followed by the AspA terminator, were purified and ligated into the EcoRI and HindIII sites of the plasmid vector pBBRIMCS4 to give the plasmid TCA313 (= pRIT14523). The codon sequenced by thioredoxin is described in ID No. 17. 2. Transformation of strain AR58 2.a To obtain strain B1011 expressing ProtD1 / 3-E7-H? S / HPV18 Plasmid pRIT14532 was introduced into E. coli AR58 (Mott et al., 1985. Proc. Nati. Acad. Sci. , 82:88) as a lysogen? defective containing a thermosensitive promoter repressor? pL, through selection for kanamycin-resistant transformants. 2.b Construction of strain B1012 expressing ProtD1 / 3-E7-His / HPV18 and thioredoxin Plasmids pRIT14532 and pRIT14523 were introduced into E. coli AR58 (Mott et al., 1985. Proc. Nati. Acad. Sci., 82: 88) as a lysogen? defective containing a thermosensitive promoter repressor? pL, through double selection for transformants resistant to kanamycin and ampicillin. 3. Development and induction of bacterial strains B1011 and B1012-expression of Prot-D1 / 3-E7-His / HPV 18 without or with thioredoxin in trans The cells of AR58 transformed with the plasmids pRTI14532 (strain B1011) and transformed AR58 cells with the plasmids pRIT14532 and pRIT14523 (Strain B1012) were developed at 30 ° C in 100 ml of LB medium supplemented with 50 μg / ml kanamycin for strain B1011 and supplemented with 50 μg / ml kanamycin and 100 μg / ml ampicillin for strain B1012. During the logarithmic phase of development, the bacteria were displaced at 39 ° C to inactivate the repressor? and to activate the synthesis of the protein D1 / 3-E7-his / HPV18 and thioredoxin. Incubation at 39 ° C was continued for 4 hours. 4. Characterization of the D1 / 3-E7-his / HIP18 fusion protein Preparation of extracts The frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. Analysis of SDS-polyacrylamide gels stained with Coomassie and Western stains After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western staining. The protDI / 3-E7-His fusion (approximately 31 kDa) was visualized through gels stained with Coomassie in the pellet fraction for strain B1011 and partially localized (30%) in the supernatant fraction for strain B1012 and it was identified in Western stains through rabbit polyclonal D-protein or N-NTA conjugate coupled to intestinal alkaline phosphatase (Qiagen cat. No. 34510), which detects the accessible histidine end. The level of expression represents approximately 1-3% of the total protein as shown in an SDS-polyacrylamide gel stained with Coomassie. For the extract of strain B1012, thioredoxin (approximately 12 kDa) was visualized through a gel stained with Coomassie in the supernatant and identified in Western stains through anti-thioredoxin monoclonal (Invitrogen R920-25) EXAMPLE X Construction of the E. coli strain B1098 expressing fusion ProtD1 / 3-E7 (cys27 -> gly, glu29 -> gn) mutated type HPB18 1. Construction of the expression plasmid Starting material a) The pRIT plasmid 14532 (= TCA 316), which codes for ProtD1 / 3-E7-His fusion, b) Plasmid LITMUS 28 (New England Biolabs cat No. 306-28), a cloning vector of pUC derivative. c) Plasmid pMG MCS Prot DI / 3 (pRIT14589) is a derivative of pMG81 (described above) where codons 4-81 of the NS1 coding region of Influenza were replaced by codons corresponding to residues 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p 119-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). Construction of plasmid pRIT 14831 (= TCA355): a plasmid expressing the mutated D1 / 3-E7 fusion protein (cys27-> gly, glu29-> gln) with the His-terminus. The Ncol-Xbal fragment for pRIT 14532 (= TCA 316), carrying the coding sequence of the E7 gene from HPV 18, elongated with a His end, was subcloned into an intermediate vector Litmus 28 useful for mutagenesis to give pRIT 14910 (= TCA348). Through analogy with mutagenesis of E7 / HPV16, double mutations cys27 - > gly and glu29 - > gln to damage the binding to the antioncogene product of the retinoblastoma gene. The introduction of mutations in the E7 gene was carried out with the Quick Change Site dírected Mutagenesis (Stratagene cat No. 200518). Since sequencing pRIT 14532 indicated the presence of a glutamic acid at position 43 of E7 instead of a glycine in the prototype sequence of HPV18, realizing that a second cycle of mutagenesis can introduce a glycine at position 43. obtained plasmid pRIT 14829 (= TCA353). After verification of the presence of mutations and the complete E7 gene integrity vector by sequencing, the mutated E7 gene was introduced into the vector pRIT 14589 (= pMG MCS ProtD1 / 3) to give the plasmid pRIT 14831 (= TCA355) . The protein and coding sequence for the mutated D1 / 3-E7 fusion protein (cys27 -> gly, glu29 -> gln) -His is described in sequence ID No. 18 and 19. 2) Construction of strain B1098 expressing mutated ProtD1 / 3-E7 (cys 27 -> gly, glu29 -> gln) His / HPV18. Plasmid pRIT 14831 was introduced into E. coli AR58 (Mott et al., 1985, Proc.Nat.Accid.Sci., 82:88), a lysogen? defective containing a thermosensitive promoter repressor? pL, to give strain B1098, selected transformants resistant to kanamycin. 3) Growth and induction of the bacterial strain B1098-expression of ProtD1 / 3-E7 mutated with (cys 27 -> gly, glu29 -> gln) His / HPV18. The AR58 cells transformed with the plasmid pRIT 14831 (strain B1098) at 30 ° C in 100 ml of the LB medium supplemented with 50 μg / ml kanamycin. During the logarithmic phase of development the bacteria were displaced at 39 ° C to activate the repressor? and activate the synthesis of mutated ProtD1 / 3-E7 -His / HPV18. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4) Characterization of ProtD1 / 3-E7 mut (cys 24 -> gly, glu26 -> gln) -His fusion, type HPV16. Frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C.

Analysis on SDS-polyacrylamide gels stained with Coomassie and Western stains After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed through SDS-polyacrylamide gel electrophoresis and Western staining. A larger band of approximately 31 kDa, located in the pellet fraction, was visualized through gels stained with Coomassie and identified in Western staining through polyclonal anti-D-protein 22 J 70 rabbit, and through Penta His (Qiagen cat No. 34660) monoclonal that detects the accessible histidine end. The level of expression represents approximately 3 to 5% of the total protein.

EXAMPLE XI Construction of the E. coli strain expressing Protein n-D1 / 3-E6-his / HPV18 1. Construction of the expression plasmid a) Plasmid pMG Prot Prot / 3 (pRIT14589) is a derivative of pMG81 (described above) where codons 4-81 of the NS1 coding region of Influenza were replaced by codons corresponding to residues 20? Thr 127 of the mature D protein of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p 119-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). This plasmid was used to express the D1 / 3-E6-his fusion protein. HPV 18 genomic type HPV E6 and E7 sequences (Colé et al., J. Mol. Biol. (1987) 193, 599-608) were amplified from the full length HPV 18 genome cloned into pBR322 (obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papillomaviruses-D69120 -Heidelberg) and were subcloned into pUC19 to give TCA302 (= pRIT14467). Construction of plasmid TCA 314 (= pRIT14526): a plasmid expressing the fusion protein D1 / 3-E6-H is / H PV18 The nucleotide sequences corresponding to amino acids 1? 158 of the E6 protein were amplified from pRIT14467. During the polymerase chain reaction, the Ncol and Spel restriction sites were generated at the 5 'and 3' ends of the E6 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give the plasmid TCA314 (= pRIT14526). The insert was sequenced to verify that no modification had been generated during the polymerase chain reaction. The protein and coding sequence for the D1 / 3-E6-His fusion protein is described in sequence ID No. 20 and 21. Transformation of strain AR58 Plasmid pRIT14526 was introduced into E. coli AR58 (Mott et al. , 1985, Proc. Nati, Acad. Sci. 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3. Development and induction of the bacterial strain-expression of Prot-D1 / 3-E6-His. AR58 cells transformed with the plasmid pRTI14526 were developed in 100 ml of the LB medium supplemented with 50 μg / ml of kanamycin at 30 ° C. During the logarithmic phase of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and to activate the synthesis of the D1 / 3-E6-his protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4. Characterization of the D1 / 3-E6-his fusion protein Frozen cells were thawed and resuspended in 10 ml of the PBS pH buffer. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed by SDS-polyacrylamide gel electrophoresis and Western staining. A band larger than approximately 32 kDa, located in the pellet fraction, was visualized through Coomassie-stained gels and identified in Western stains through the rabbit polyclonal anti-protein D and through the Ni-NTA conjugate coupled to the calf intestinal alkaline phosphatase (Qiagen cat. No. 34510), which detects the accessible histidine end. The level of expression represents approximately 3-5% of the total protein EXAMPLE XII Construction of an E. coli strain expressing the D1 / 3-E6E7-his / HPV18 fusion protein 1. Construction of the expression plasmid. a) Plasmid pMG MCS Prot DI / 3 (pRIT14589) is a derivative of pMG81 (described above) where codons 4-81 of the NS1 coding region of Influenza were replaced by codons corresponding to residues 20? Thr 127 of mature protein D of strain 772 of Haemophilus Influenzae, biotype 2 (H. Janson et al., 1991, Infection and Immunity, Jan. p.129-125). The sequence of Prot-D1 / 3 is followed by a multiple cloning site (11 residues) and a coding region for one end of C-terminal histidine (6 His). This plasmid was used to express the D1 / 3-E6E7-his fusion protein. b) HPV 18 genotype type HPV E6 and E7 sequences (Colé et al., J. Mol. Biol. (1987) 193, 599-608) were amplified from the HPV 18 full length genome cloned into pBR322 ( obtained from Deutsches Krebsforschungszentrum (DKFZ), Referenzzentrum fur human pathogen Papillomaviruses-D69120 -Heidelberg) and subcloned into pUC19 to give TCA302 (= pRIT14467). c) The coding sequences for E6 and E7 in TCA302 (= pRIT14467) were modified with an adapter of synthetic oligonucleotides (inserted between the Hga and Nsi sites) by introducing a deletion of 11 nucleotides between the E6 and E7 genes by removing the stop codon of E6 and creating coding sequences of E6 and E7 fused in plasmid TCA320 (= pRIT 14618). Construction of plasmid TCA 328 (= pRIT14567): a plasmid expressing the fusion protein D1 / 3-E6E7-His / HPV18 The nucleotide sequences corresponding to amino acids 1? 263 of the fused E6E7 protein were amplified from pRIT14618. During the polymerase chain reaction, the Ncol and Spel restriction sites were generated at the 5 'and 3' ends of the fused E6E7 sequences allowing the insertion in the same sites of the plasmid pMGMCS Prot D1 / 3 to give plasmid TCA328 ( = pRIT14567). The insert was sequenced to verify that no modification had been generated during the polymerase chain reaction. The protein and coding sequence for the D1 / 3-E6E7-His fusion protein is described in sequence ID No. 22 and 23. Transformation of strain AR58 Plasmid pRIT14567 was introduced into E. coli AR58 (Mott et al. , 1985, Proc. Nati, Acad. Sci. 82:88) a lysogen? defective containing a thermosensitive promoter repressor? pL. 3. Development and induction of the bacterial strain-expression of Prot-D1 / 3-E6E7-His AR58 cells transformed with the plasmid pRTI14512 were developed in 100 ml of the LB medium supplemented with 50 μg / ml of kanamycin at 30 ° C. During the logarithmic e of growth, the bacteria were displaced at 39 ° C to inactivate the repressor? and to activate the synthesis of the D1 / 3-E6E7-his protein. Incubation at 39 ° C was continued for 4 hours. Bacteria were formed into pellets and stored at -20 ° C. 4. Characterization of the D1 / 3-E6E7-his fusion protein. Frozen cells were thawed and resuspended in 10 ml of the pH buffer of PBS. The cells were broken in a French pressure cell press SLM Aminco at 1,406 kg / cm 2 (three passages). The extract was centrifuged at 16,000 g for 30 minutes at 4 ° C. After centrifugation of the extracts described above, aliquots of supernatant and pellet were analyzed by SDS-polyacrylamide gel electrophoresis and Western staining. A main band of approximately 48 kDa, located in the pellet fraction, was visualized through gels stained with Coomassie and identified in Western stains through the rabbit polyclonal anti-protein D and through the Ni-NTA conjugate coupled to the calf intestinal alkaline phosase (Qiagen cat. No. 34510), which detects the accessible histidine end. The level of expression represents approximately 1% of the total protein.

EXAMPLE XIII The therapeutic potential of the vaccine containing the PD1 / 3 E7 fusion protein and different CpG oligonucleotides was evaluated on TC1 (tumor model expressing E7). 1. Therapeutic experiments: protocol CT1, E7 expressing tumor cells were injected intravenously (200 μl) 10e6 cells on the flank of C57BL / 6 nimmunocompetent mice. Mice were vaccinated 7 and 14 days after tumor attack, with 50 μg of ProtD1 / 3 E7 HPV16 injected between the jump (100 μl: 50 μ / jump) in the presence of different adjuvants: 2 and 4 weeks after the second immunization , 5 mice / group were annihilated and spleens or popliteal lymph nodes were collected and analyzed for immune response. 1.2 Results Groups of mice 1) PBS 2) ProtD1 / 3 E7 HPV16 3) ProtD1 / 3 E7 HPV16 + oligo: 1: 1826 (WD 1001): TCT ATG ACG TTC CTG ACGTT 4) Oligo 5) ProtD1 / 3 E7 HPV16 + oligo 2/1758 (WD1002): TCT CCC AGC GTG CGC CAT 6) Oligo Tumor growth This was verified by measuring the individual tumors twice a week.

Figure 1: represents the mean tumor growth (in mm2) / group n = 10 followed by 4 weeks. • Injection of 10e6 of TC1 cells injected subcutaneously gave rise to a developing tumor in 100% of the animals. • Vaccination with ProtD1 / 3E7 or only the auxiliary: 100% of the animals developed a tumor. • As shown in Figures 1 and 2, in the groups of mice that received the antigen with a CpG oligonucleotide, the mean tumor growth remained very low and very similar between groups, reflecting that the tumor development was either reduced or that several tumors were completely rejected.

The analysis of the individual tumor growth 2 and 4 weeks after the last vaccination showed that the complete rejection in the groups are: Day 28 (n = 10) Day 42 (n = 5) E7 + oligo (1826) 49% 40% Oligo 1 0% 0% E7 + oligo2 (1758) 70% 40% Oligo 2 0% 0% The average tumor growth / group of mice vaccinated with PD1 / 3 E7 + the CpG oligos are quite similar and the analysis of the individual tumor development showed that the CpG oligos induce a prolonged rejection of a complete tumor.

Conclusion Both CpG (Oligo 2> oligo 1) induced complete tumor regression. The lymphoproliferative response was analyzed through in vitro restimulation of cells from spleen and lymph nodes for 72 hours with either PD1 / 3E7, E7 protein (Bollen) and PD (whole) PD1 / 3 (coated or without latex beads) (10, 1, 0.1 μg / ml) 2 and 4 weeks after II. • Positive controls (ConA stimulation) were positive. • Surprisingly, no specific proliferative response in E7 and non-specific PD can be observed during the start with spleen cells 2 or 4 weeks after II (probably due to the technical problem: data not shown).

• Otherwise, the lymph node cells of mice that received Prot D1 / 3 E7 in CpG oligos 1 and 2 showed a very good E7-specific proliferative response although almost no specific PD response (whole) can be observed even at the same time. highest concentration of 100 μg / ml non-specific PD1 / 3 responses that were observed even when coated on latex beads. Similar data were obtained 4 weeks after II. Serology The anti-E7 antibody response: IgG and isotopes (IgG1, IgG2a, IgG2b, IgGTot) were measured through ELISA using the E7 protein as coating antigen as described in the materials and methods section. Figures 3 and 4 show the relative percentage of the different IgG isotopes in a total of IgG, 2 and 4 weeks after the II respectively. • The oligos affect only weakly (oligo II) or not all oligo I, the weak antibody response was observed when only PD1 / 3E7 was used. • The predominant E7-specific antibody subclass was clearly lgG2b for all tested formulation (80-90% of total IgG). The same results were obtained 4 weeks after II.

Isotypic profile of anti-E7 responses (after II, poured serum) exp. 97293 CTL assay A CTL response could be detected when measured 2 weeks after the last vaccination, when cells were re-stimulated in vitro with irradiated TC1, when TC1 or E7 peptide pulsed by EL4, were used as target cells, when mice immunized with PD1 / 3 E7 + CpG oligo 2 > 1 (25-40% specific lysis) and not only with the oligo. • The lysis was seen on TC1 cells than on the pulsed E7 EL4 cells of the peptide, but mostly they were observed in the groups of mice vaccinated with PD1 / 3E7 + CpG oligos (2> 1). In this experiment, other formulations did not induce a CTL. • Using EL4 cells pulsed with E7, no lysis was observed when the mice received the protein or only the auxiliary. 1. 3 Materials and Methods 1. 3.1 Formulation process All the formulations were prepared on the day of the injection. Formulations containing oligo Formulations containing oligo alone without another auxiliary were prepared through the addition of CpG to PrtD1 / 3-E7 diluted in PBS pH 7.4. The auxiliary controls without antigen if it is prepared by replacing the protein through PBS. 1. 3.2 Mouse or Cell Lines C57B1 / 6 (Iffa Credo) mice aged 6-8 weeks were used in these experiments. Cell lines: TC1 (obtained from John Hopkin University), or EL4 cells were developed in RPMI 1640 (BioWhittaker) containing 10% FCS and additives; 2 mm L-glutamine, 1% antibiotics (10000 U / ml penicillin, 10000 μg / ml streptomycin), 1% non-essential amino acid 100x, 1% sodium pyruvate (Gibco), 5 10e-5 M of 2-mercaptoethanol. Prior to injection, the TC1 cells were trypsinized and washed in a serum-free medium. 1.3.3 Tumor growth All animals were injected with tumor cells on day 0 and randomized on day 7. Individual tumor growth was followed with time (2 mean diameters (A and B)) were measured using calibrators 2 times a week, A x B represent "the tumor surface" and the average of 5 values / groups was shown in the graph over time: 6 weeks. 1. 3.4 Reading CMI Lymphoproliferation in vitro Lymphoproliferation was performed on individual spleens and lymph node combinations. 200,000 spleen or epithelial lymph node cells were plated in triplicate in 96-well microplates in RPMI medium containing 1% serum from normal and active mice. After 72 hours of in vitro restimulation with different amounts of PD1 / 3 (1, 0.1, 0.001 μg / ml) or E7 (10-1-0.1 μg / ml), after 72 hours, 100 μl of the supernatant was removed of culture and were replaced by a fresh medium containing 1 μC and 3H thymidine (Amersham 5Ci / mmoles). After 16 hours, the cells were harvested on filter plates. The incorporated radioactivity was counted in a β-counter. The results are expressed in CPM (mean of cavities in triplicate) or as indices of stimulation (average CPM in cultures with antigen / average CPM in cultures without antigen). 1.3.5 CTL assay 20 spleen cells of 10e6 were cocultivated with 2 irradiated 10e6 TC1 (18000r) cells (E7 expression tumor) for 7 days in the presence or absence of ConA sup. (2%). The target cells used to determine cytotoxicity were either Cr51 loading cells (DuPont NEN 37MBq / ml) (1 hour at 37 ° C) or EL4 cells pulsed with E7 (for 1 hour at 37 ° C) during loading Cr 51 of the cells 10 μg / ml of the peptide derived from E7 (49-57) (QCB) compared to EL4 cells, the NK-dependent lysis was determined in K562 target cells, 2000 target cells / cavity were added from a plate of 96 cavities (V-shaped bottom nunc 2-45128) with 100/1 being the highest effector / objective ratio. The controls for the release of spontaneous or maximal Cr51 were performed 6 times and were objective in the medium and 1.5% triton. All plates were moderately centrifuged and incubated for 4 hours at 37 ° C in 7% CO2. 50 μl of the supernatant was deposited on Lumaplate (Packard), allowed to dry O / N and counted in a Top Count counter. The data were expressed as a percentage of specific lysis, which was calculated from c. p. m. through the formula (experimental release-spontaneous release) / (maximum release-spontaneous release) X 100.

Serology The quantification of the anti-E7 antibody was performed through ELISA using the E7as coating antigen. The antigen and antibody solutions were used at 50 μl per well. The antigen was diluted to a final concentration of 3 μg / ml) in carbonate pH buffer, pH 9.5, and was adsorbed overnight at 4 ° C in the 96-well microtiter plate cavities (Maxisorb Immuno-plate, Nuc, Denmark). The plates were then incubated for 1 hour at 37 ° C with PBS containing 1% bovine serum albumin and 0.1% Tween 20 (saturation pH regulator). Two dilutions of serum (starting at 1/100 dilution) in the saturation pH regulator were added to the E7 coated plates and incubated for 1 1 / hour at 37 ° C. The plates were washed 3 times with PBS at 0. |%, Tween 20 and IgG 1, IgG2a or IgGtot IgGtot or anti-mouse IgGtot, conjugated with biotin (Amersham, UK) diluted 1/5000 in saturation pH regulator was added to each cavity and incubated for 1 hour at 37 ° C. After the wash step, the biotinylated streptavidin-peroxidase complex (Amersham, UK) diluted 1/5000 in saturation pH buffer was added for an additional 30 minutes at 37 ° C. The plates were washed as above and incubated for 10 minutes with TMB (tetramethyl-benzidine). The reaction was quenched with 4N H2SO4 and read at 450 nm. The midpoint dilutions were calculated through SoftmaxPro (using a parameter equation).

EXAMPLE XIV In a second experiment, the vaccine of the invention was tested to determine the importance of the base structure. Therapeutic experiment: protocol • 10e6 TC1 cells, tumor cells expressing E7: were injected subcutaneously (200 μl) on the flank of immunocompetent C57BL / 6 mice. • 2 vaccinations, 7 and 14 days after the tumor attack, with 5 μ ProtD 1/3 E7 HPV16 intra-action (100 μl: 50 μl / action) +/- CpG oligo; Oligon 1 (WD1001) as a modified phosphorothioate or Oligo itself (WD1006) but with a phosphodiester bond. • 5 animals / group. Tumor development was verified by measuring the individual tumors twice a week and the average tumor growth / group of 5 animals is illustrated in Figure 5 and shows that the phosphorothioate-modified oligonucleotides are effective in producing tumor regression.

Conclusions • All animals that received TC1 10e6 tumor cells developed a growing tumor. • 100% of the animals were vaccinated twice, 7 days apart, only with the PD1 / 3 E7 HPV16 protein that develops a tumor. • 100% of the animals that received PD1 / 3E7 protein + oligo WD1006 develops a tumor at the concentrations tested. • All groups of animals that received the E7 + CpG 1001 protein at a concentration ranging from 10 to 200 μg showed partial or complete tumor regression (20-40%) The first concentration at which this therapeutic effect on lung regression is not completely obtained is E7 + 1μg CpG oligo 1001.

EXAMPLE XV In a third series of experiments, the vaccines of the invention were evaluated in transgenic mice expressing the E7 protein. • The transgenic mouse strain was generated by M. Parmentier and C. Ledent at the IRIBHN (ULB). (Ref: PNAS (E.U.A.) 1990, 87; 6176-6176-6180). • Since the transgenic mice live with the E7 HPV16 gene since they are born, they consider it "tolerant" to this gene: E7 of HPV 16, in this situation it is considered as an "independent antigen".

• The expression of the transgene was triggered by the thyroglobulin promoter. Since thyroglobulin is constitutively expressed only in the thyroid, E7 is expressed in the thyroid. • As a consequence of this expression, the thyroid cells proliferate, the mouse develops tremors and nodes, which after 6 months to a year can become an invasive cancer. The results (Figure 6) of the experiments of the experiments show that therapeutic vaccination with the CpG oligonucleotide and the antigen as described above, results in a reduction of tumor growth and can induce a complete tumor regression.

Materials and Methods • Cells 10e6 TC1 cells, tumor cells expressing E7: were injected subcutaneously (200 μl) into the flank of male or female transgenic C57BL / 6 mice. • They were vaccinated 7 and 14 days after the tumor attack, with 5 μg ProtD 1/3 E7 HPV16 injected between the junction (100 μl: 50 μl / binding) in the presence of 2 of the oligonucleotides CpG TCT CCC AGC GTG CGC CAT and two control auxiliaries. • 10 animals / group 2 and 4 weeks after the second immunization the mice were annihilated and the spleens or lympho propliteal.

Conclusion The vaccines of the invention are effective to produce tumor regression in tumors induced by HPV.

LIST OF SEQUENCES (1) GENERAL INFORMATION (i) APPLICANT: BRUCK, CLAUDINE (ii) TITLE OF THE INVENTION: VACCINATE (iii) NUMBER OF SEQUENCES: 23 (iv) ADDRESS OF CORRESPONDENCE: (A) RECIPIENT: SmithKIine Beechma (B) STREET: 2 New Horizons Court, Great West Road, B (C) CITY: Middx (D) STATE: (E) COUNTRY: UK (F) AREA: TW8 9EP (v) COMPUTER LEGIBLE FORM: (A) TYPE OF MEDIA: Floppy disk ( B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ for Windows Version 2.0 (vi) CURRENT REQUEST DATA: (A) APPLICATION NUMBER: (B) SUBMISSION DATE: (C) CLASSIFICATION: (vii) PREVIOUS APPLICATION DATA: (A) APPLICATION NUMBER: (B) SUBMISSION DATE: (viii) APPORTER / AGENT INFORMATION: (A) NAME: Dalton, Marcus J. (B) REGISTRATION NUMBER: (C) ) REFERENCE / POWDER NUMBER: B45124 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 0181 9756348 (B) TELEFAX: 0181 9756177 (C) TELEX: (2) INFORMATION FOR SEQ ID NO: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E7 his (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Met Asp Pro Ser Ser His Ser Being As Met Met Wing Asn Thr Gln Met Lys 1 5 10 15 Ser Asp Lys lie He He Wing Kis Arg Gly Wing Ser Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 lie His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Ala Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu 115 120 125 Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser 130 135 140 Ser Glu Glu Glu Asp Glu He Asp Gly Pro Wing Gly Gln Ala Glu Pro 145 150 155 160 Asp Arg Ala His Tyr Asn He Val Thr Phe Cys Cys Lys Cys Asp Ser 165 170 175 Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp He Arg Thr Leu 180 185 190 Glu Asp Leu Leu Met Gly Thr Leu Gly He Val Cys Pro He Cys Ser 195 200 205 Gln Lys Pro Thr Ser Gly His His His His His His His 210 215 220 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 663 amino acids (B) TYPE: nucleic acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear D protein 1/3 E7 his (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGCATGGAGA TACACCTACA 360 TTGCATGAAT A TATGTTAGA TTTGCAACCA GAGACAACTG ATCTCTACTG TTATGAGCAA 420 TTAAATGACA GCTCAGAGGA GGAGGATGAA ATAGATGGTC CAGCTGGACA AGCAGAACCG 480 GACAGAGCCC ATTACAATAT TGTAACCTTT TGTTGCAAGT GTGACTCTAC GCTTCGGTTG 540 TGCGTACAAA GCACACACGT AGACATTCGT ACTTTGGAAG ACCTGTTAAT GGGCACACTA 600 GGAATTGTGT GCCCCATCTG TTCTCAGAAA CCAACTAGTG GCCACCATCA CCATCACCAT 660 TAA 663 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 822 base pairs (B) TYPE: nucleic acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: Linear Protein D 1/3 E6 His / HPV16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGTTTCAGGA CCCACAGGAG 360 CGACCCAGAA AGTTACCACA GTTATGCACA GAGCTGCAAA CAACTATACA TGATATAATA 420 TTAGAATGTG TGTACTGCAA GCAACAGTTA CTGCGACGTG AGGTATATGA CTTTGCTTTT 480 CGGGATTTAT GCATAGTATA TAGAGATGGG AATCCATATG CTGTATGTGA TAAATGTTTA 540 AAGTTTTATT CTAAAATTAG TGAGTATAGA CATTATTGTT ATAGTTTGTA TGGAACAACA 600 TTA GAACAGC AATACAACAA ACCGTTGTGT GATTTGTTAA TTAGGTGTAT TAACTGTCAA 660 AAGCCACTGT GTCCTGAAGA AAAGCAAAGA CATCTGGACA AAAAGCAAAG ATTCCATAAT 720 ATAAGGGGTC GGTGGACCGG TCGATGTATG TCTTGTTGCA GATCATCAAG AACACGTAGA 780 GAAACCCAGC TGACTAGTGG CCACCATCAC CATCACCATT AA 822 (2) INFORMATION FOR SEQ ID NO: 4: (i) CHARACTERISTICS OF SEQUENCE: (A) LENGTH: 274 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 His / HPV 16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His Asp His Phe Leu Asp Gly Leu Thr Asp Val Wing Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu Pro Gln Leu 115 120 125 Cys Thr Glu Leu Gln Thr Thr He His Asp He He Leu Glu Cys Val 130 135 140 Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe 145 150 155 160 Arg Asp Leu Cys He Val Tyr Arg Asp Gly Asn Pro Tyr Wing Val Cys 165 170 175 Asp Lys Cys Leu Lys Phe Tyr Ser Lys He Ser Glu Tyr Arg His Tyr 180 135 190 Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro 195 200 205 Leu Cys Asp Leu Leu He Arg Cys He Asn Cys Gln Lys Pro Leu Cys 210 215 220 Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn 225 230 235 240 He Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser 245 250 255 Arg Thr Arg Arg Glu Thr Gln Leu Thr Ser Gly His His His His His 260 265 270"His (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1116 base pairs (B) TYPE: nucleic acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 / E7 HPV16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGTTTCAGGA CCCACAGGAG 360 CGACCCAGAA AGTTACCACA GTTATGCACA GAGCTGCAAA CAACTATACA TGATATAATA 420 TTAGAATGTG TGTACTGCAA GCAACAGTTA CTGCGACGTG AGGTATATGA CTTTGCTTTT 480 CGGGATTTAT GCATAGTATA TAGAGATGGG AATCCATATG CTGTATGTGA TAAATGTTTA 540 AAGTTTTATT CTAAAATTAG TGAGTATAGA CATTATTGTT ATAGTTTGTA TGGAACAACA 600 TTAGAACAGC AATACAACAA ACCGTTGTGT GATTTGTTAA TTAGGTGTAT TAACTGTCAA 660 AAGCCACTGT GTCCTGAAGA AAAGCAAAGA CATCTGGACA AAAAGCAAAG ATTCCATAAT 720 ATAAGGGGTC GGTGGACCGG TCGATGTATG TCTTGTTGCA GATCATCAAG AACACGTAGA 780 GAAACCCAGC TGATGCATGG AGATACACCT ACATTGCATG AATATATGTT AGATTTGCAA 840 CCAGAGACAA CTGATCTCTA CTGTTATGAG CAATTAAATG ACAGCTCAGA GGAGGAGGAT 900 GAAATAGATG GTCCAGCTGG ACAAGCAGAA CCGGACAGAG CCCATTACAA TATTGTAACC 960 TTTTGTTGCA AGTGTGACTC TACGCTTCGG TTGTGCGTAC AAAGCACACA CGTAGACATT 1020 CGTACTTTGG AAGACCTGTT AATGGGCACA CTAGGAATTG TGTGCCCCAT CTGTTCTCAG 1080 AAACCAACTA GTGGCCACCA TCACCATCAC CATTAA 1116 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 / E7 / HPV16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Met Phe Gln ASD Pro Gln Glu Arg Pro Arg Lys Leu Pro Gln Leu 115"120 125 Cys Thr Glu Leu Gln Thr Thr He His Asp He He Leu Glu Cys Val 130 135 140 Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Wing Phe 145 150 155 160 Arg Asp Leu Cys He Val Tyr Arg Asp Gly Asn Pro Tyr Wing Val Cys 165 170 175 Asp Lys Cys Leu Lys Phe Tyr Ser Lys He Ser Glu Tyr Arg His Tyr 180 185 190 Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro 195 200 205 Leu Cys Asp Leu Leu He Arg Cys He Asn Cys Gln Lys Pro Leu Cys 210 215 220 Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn 225 230 235 240 He Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser 245 250 255 Arg Thr Arg Glu Thr Gln Leu Met His Gly Asp Thr Pro Thr Leu 260 265 270 His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys 275 280 285 Tyr Glu Gln Leu Asn Asp Ser Glu Glu Glu Asp Glu He Asp Gly 290 295 300 Pro Wing Gly Gln Wing Glu Pro Asp Arg Wing His Tyr Asn He Val Thr 305 310 315 320 Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr 325 330 335 His Val Asp He Arg Thr Leu Glu Aßp Leu Leu Met Gly Thr Leu Gly 340 345 350 He Val Cys Pro He Cys Ser Gln Lys Pro Thr Ser Gly His His His 355 360 365 His His His 370 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 663 base pairs (B) TYPE: nucleic acid (C) ESTR U CT U RA D E NA: ind ividual (D) TOPOLOGY: linear Protein D 1/3 E7 HPV16 mutated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGCATGGAGA TACACCTACA 360 TTGCATGAAT ATATGTTAGA TTTGCAACCA GAGACAACTG ATCTCTACGG TTATCAGCAA 420 TTAAATGACA GCTCAGAGGA GGAGGATGAA ATAGATGGTC CAGCTGGACA AGCAGAACCG 480 GACAGAGCCC ATTACAATAT TGTAACCTTT TGTTGCAAGT GTGACTCTAC GCTTCGGTTG 540 TGCGTACAAA GCACACACGT AGACATTCGT ACTTTGGAAG ACCTGTTAAT GGGCACAC TA 600 GGAATTGTGT GCCCCATCTG TTCTCAGAAA CCAACTAGTG GCCACCATCA CCATCACCAT 660 TAA 663 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 220 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E7 HPV 16 mutated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His Asp His Phe Leu Asp Gly Leu Thr Asp Val Wing Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu 115 120 125 Gln Pro Glu Thr Thr Asp Leu Tyr Gly Tyr Gln Gln Leu Asn Asp Ser 130 135 140 Ser Glu Glu Glu Asp Glu He Asp Gly Pro Wing Gly Gln Wing Glu Pro 145 150 155 160 Asp Arg Wing His Tyr Asn He Val Thr Phe Cys Cys Lys Cvs Asp Ser 165 170 175 Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp He Arg Thr Leu 180 185 190 Glu Aso Leu Leu Met Gly Thr Leu Gly He Val Cys Pro He Cys Ser 195 200 205 Gln Lys Pro Thr Ser Gly His His His His His His (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 879 base pairs (B) TYPE : nucleic acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear CLYTA E6 His HPV 16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ATGAAAGGGG GAATTGTACA TTCAGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60 AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120 CACACAGACG GCAACTGGTA CTGGTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180 AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240 AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGGT ATCAAATGCC 300 TTTATCCAGT CAGCGGACGG AACAGGCTGG TACTACCTCA AACCAGACGG AACACTGGCA 360 GACAGGCCAG AATTGGCCAG CATGC TGGAC ATGGCCATGT TTCAGGACCC ACAGGAGCGA 420 CCCAGAAAGT TACCACAGTT ATGCACAGAG CTGCAAACAA CTATACATGA TATAATATTA 480 GAATGTGTGT ACTGCAAGCA ACAGTTACTG CGACGTGAGG TATATGACTT TGCTTTTCGG 540 GATTTATGCA TAGTATATAG AGATGGGAAT CCATATGCTG TATGTGATAA ATGTTTAAAG 600 TTTTATTCTA AAATTAGTGA GTATAGACAT TATTGTTATA GTTTGTATGG AACAACATTA 660 GAACAGCAAT ACAACAAACC GTTGTGTGAT TTGTTAATTA GGTGTATTAA CTGTCAAAAG 720 CCACTGTGTC CTGAAGAAAA GCAAAGACAT CTGGACAAAA AGCAAAGATT CCATAATATA 780 AGGGGTCGGT GGACCGGTCG ATGTATGTCT TGTTGCAGAT CATCAAGAAC ACGTAGAGAA 840 ACCCAGCTGA CTAGTGGCCA CCATCACCAT CACCATTAA 879 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear CLYTA E6 His HPV 16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Lys Gly Gly He Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys 1 5 10 15 Phe Glu Lys He Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr 20 25 30 Met Leu Wing Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp 35 40 45 Phe Asp Asn Ser Gly Glu Met Wing Thr Gly Trp Lys Lys He Wing Asp 50 55 60 Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Wing Met Lys Thr Gly Trp Val 65 70 75 80 Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Wing Lys Glu Gly Wing Met 85 90 95 Val Ser Asn Wing Phe He Gln Wing Wing Asp Gly Thr Gly Trp Tyr Tyr 100 105 110 Leu Lys Pro Asp Gly Thr Leu Wing Asp Arg Pro Glu Leu Ala Ser Met 115 120 125 Leu Asp Met Wing Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu 130 135 140 Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr He His Asp He He Leu 145 150 155 160 Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp 165 170 175 Phe Wing Phe Arg Asp Leu Cys He Val Tyr Arg Asp Gly Asn Pro Tyr 180 185 190 Wing Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys He Ser Glu Tyr 195 200 205 Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr 210 215 220 Asn Lys Pro Leu Cys Asp Leu Leu He Arg Cys He Asn Cys Gln Lys 225 230 235 240 Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg 245 250 255 Phe His Asn He Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys 260 265 270 Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu Thr Ser Gly His His 275 280 285 His His His His 290 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 720 base pairs (B) TYPE: nucleic acid (C) STRUCTURE CHAIN: single (D) TOPOLOGY: linear CLYTA E7 HIS HPV 16 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 11: ATGAAAGGGG GAATTGTACA TTCAGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60 AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120 CACACAGACG GCAACTGGTA CTGGTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180 AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240 AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGGT ATCAAATGCC 300 TTTATCCAGT CAGCGGACGG AACAGGCTGG TACTACCTCA AACCAGACGG AACACTGGCA 360 GACAGGCCAG AATTGGCCAG CATGCTGGAC ATGGCCATGC ATGGA GATAC ACCTACATTG 420 CATGAATATA TGTTAGATTT GCAACCAGAG ACAACTGATC TCTACTGTTA TGAGCAATTA 480 AATGACAGCT CAGAGGAGGA GGATGAAATA GATGGTCCAG CTGGACAAGC AGAACCGGAC 540 AGAGCCCATT ACAATATTGT AACCTTTTGT TGCAAGTGTG ACTCTACGCT TCGGTTGTGC 600 GTACAAAGCA CACACGTAGA CATTCGTACT TTGGAAGACC TGTTAATGGG CACACTAGGA 660 ATTGTGTGCC CCATCTGTTC TCAGAAACCA ACTAGTGGCC ACCATCACCA TCACCATTAA 720 (2) INFORMATION FOR SEQ ID NO: 11: ( i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear CLYTA E7 HIS HPV 16 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12 : Met Lys Gly Gly He Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys 1 5 10 15 Phe Glu Lys He Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr 20 25 30 Met Leu Wing Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp 35 40 45 Phe Asp Asn Ser Gly Glu Met Wing Thr Gly Trp Lys Lys He Wing Asp 50 55 60 Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Wing Met Lys Thr Gly Trp Val 65 70 75 80 Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Wing Lys Glu Gly Wing Met 85 90 95 Val Ser Asn Wing Phe He Gln Wing Wing Asp Gly Thr Gly Trp Tyr Tyr 100 105 110 Leu Lys Pro A3p Gly Thr Leu Wing Asp Arg Pro Glu Leu Ala Ser Met 115 120 125 Leu Asp Met Ala Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met 130 135 140 Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu 145 150 155 160 Asn Asp Ser Glu Glu Glu Asp Glu He Asp Gly Pro Wing Gly Gln 165 170 175 Wing Glu Pro Asp Arg Wing His Tyr Asn He Val Thr Phe Cys Cys Lys 180 185 190 Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp He 195 200 205 Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly He Val Cys Pro 210 215 220 He Cys Ser Gln Lys Pro Thr Ser Gly His His His His His Hxs 225 230 235 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1173 base pairs (B) ) TYPE: nucleic acid (C) chain structure: single (D) TOPOLOGY: linear CLYTA E6E7 His HPV16 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 13: ATGAAAGGGG GAATTGTACA TTCAGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60 AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120 CACACAGACG GCAACTGGTA CTGGTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180 AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240 AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGGT ATCAAATGCC 300 TTTATCCAGT CAGCGGACGG AACAGGCTGG TACTACCTCA AACCAGACGG AACACTGGCA 360 GACAGGCCAG AATTGGCCAG CATGCTGGAC ATGGCCATGT TTCAGGACCC ACAGGAGCGA 420 CCCAGAAAGT TACCACAGTT ATGCACAGAG CTGCAAACAA CTATACATGA TATAATATTA 480 GAATGTGTGT ACTGCAAGCA ACAGTTACTG CGACGTGAGG TATATGACTT TGCTTTTCGG 540 GATTTATGCA TAGTATATAG AGATGGGAAT CCATATGCTG TATGTGATAA ATGTTTAAAG 600 TTTTATTCTA AAATTAGTGA GTATAGACAT TATTGTTATA GTTTGTATGG AACAACATTA 660 GAACAGCAAT ACAACAAACC GTTGTGTGAT TTGTTAATTA GGTGTATTAA CTGTCAAAAG 720 CCACT GTGTC CTGAAGAAAA GCAAAGACAT CTGGACAAAA AGCAAAGATT CCATAATATA 780 AGGGGTCGGT GGACCGGTCG ATGTATGTCT TGTTGCAGAT CATCAAGAAC ACGTAGAGAA 840 ACCCAGCTGA TGCATGGAGA TACACCTACA TTGCATGAAT ATATGTTAGA TTTGCAACCA 900 GAGACAACTG ATCTCTACTG TTATGAGCAA TTAAATGACA GCTCAGAGGA GGAGGATGAA 960 ATAGATGGTC CAGCTGGACA AGCAGAACCG GACAGAGCCC ATTACAATAT TGTAACCTTT 1020 TGTTGCAAGT GTGACTCTAC GCTTCGGTTG TGCGTACAAA GCACACACGT AGACATTCGT 1080 ACTTTGGAAG ACCTGTTAAT GGGCACACTA GGAATTGTGT GCCCCATCTG TTCTCAGAAA 1140 CCAACTAGTG GCCACCATCA CCATCACCAT TAA 1173 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 391 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear CLYTA E6E7 His HPV16 ( xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Lys Gly Gly He Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys 1 5 10 15 Phe Glu Lys He Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr 20 25 30 Met Leu Wing Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp 40 45 Phe Asp Asn Ser Gly Glu Met Wing Thr Gly Trp Lys Lys He Wing Asp 50 55 60 Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Wing Met Lys Thr Gly Trp Val 65 70 75 80 Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Wing Lys Glu Gly Wing Met 85 90 95 Val Ser Asn Wing Phe He Gln Wing Wing Asp Gly Thr Gly Trp Tyr Tyr 100 105 110 Leu Lys Pro Asp Gly Thr Leu Wing Asp Arg Pro Glu Leu Ala Ser Met 115 120 125 Leu Asp Met Wing Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu 130 135 140 Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr He His Asp He He Leu 145 150 155 160 Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp 165 170 175 Phe Wing Phe Arg Asp Leu Cys He Val Tyr Arg Asp Gly Asn Pro Tyr 180 185 190 Wing Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys He Ser Glu Tyr 195 200 205 Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr 210 215 220 Asn Lys Pro Leu Cys Asp Leu Leu He Arg Cys lie Asn Cys Gln Lys 225 230 235 240 Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg 245 250 255 Phe His Asn He Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys 260 265 270 Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu Met His Gly Asp Thr 275 280 285 Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp 290 295 300 Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu Glu Asp Glu 305 310 315 320 He Asp Gly Pro Wing Gly Gln Wing Glu Pro Asp Arg Wing His Tyr Asn 325 330 335 He Val Thr Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg Leu Cys Val 340 345 350 Gln Ser Thr His Val Asp He Arg Thr Leu Glu Asp Leu Leu Met Gly 355 360 365 Thr Leu Gly He Val Cys Pro He Cys Ser Gln Lys Pro Thr Ser Gly 370 375 380 His His His His His His His 385 390 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 684 base pairs (B) TYPE: nucleic acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E7 His HPV 18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGCATGGACC TAAGGCAACA 360 TTGCAAGACA TTGTATTGCA TTTAGAGCCC CAAAATGAAA TTCCGGTTGA CCTTCTATGT 420 CACGAGCAAT TAAGCGACTC AGAGGAAGAA AACGATGAAA TAGATGAAGT TAATCATCAA 480 CATTTACCAG CCCGACGAGC CGAACCACAA CGTCACACAA TGTTGTGTAT GTGTTGTAAG 540 TGTGAAGCCA GAATTGAGCT AGTAGTAGAA AGCTCAGCAG ACGACCTTCG AGCATTCCAG 600 CAGCTG TTTC TGAACACCCT GTCCTTTGTG TGTCCGTGGT GTGCATCCCA GCAGACTAGT 660 GGCCACCATC ACCATCACCA TTAA 684 (2) INFORMATION FOR SEQ ID NO: 16: (!) SEQUENCE CHARACTERISTICS: (A) LENGTH: 228 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E7 his HPV 18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Met His Gly Pro Lys Wing Thr Leu Gln Asp He Val Leu His Leu 115 120 125 Glu Pro Gln Asn Glu He Pro Val Asp Leu Leu Cys His Glu Gln Leu 130 135 140 Ser Asp Ser Glu Glu Glu Asn Asp Glu He Asp Glu Val Asn His Gln 145 150 155 160 His Leu Pro Wing Arg Arg Wing Glu Pro Gln Arg His Thr Met Leu Cys 165 170 175 Met Cys Cys Lys Cys Glu Wing Arg He Glu Leu Val Val Glu Ser Ser 180 185 190 Wing Asp Asp Leu Arg Wing Phe Gln Gln Leu Phe Leu Asn Thr Leu Ser 195 200 205 Phe Val Cys Pro Trp Cys Ala Ser Gln Gln Thr Ser Gly His His His 210 215 220 His His His 225 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY : Linear Thioredoxin (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Met Ser Asp Lys He He His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15 Val Leu Lys Wing Asp Gly Wing He Leu Val Asp Phe Trp Wing Glu Trp 20 25 30 Cys Gly Pro Cys Lys Met Wing Pro Pro Le Leu Asp Glu He Wing Asp 35 40 45 Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn He Asp Gln Asn 50 55 60 Pro Gly Thr Wing Pro Lys Tyr Gly He Arg Gly He Pro Thr Leu Leu 65 70 75 80 Leu Phe Lys Asn Gly Glu Val Wing Wing Thr Lys Val Gly Wing Leu Ser 85 90 95 Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala 100 105 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 684 base pairs (B) TYPE: nucleic acid (C) CHAIN STRUCTURE: individual ( D) TOPOLOGY: linear Protein D 1/3 E7 HPV18 mutated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCCA TGCATGGACC TAAGGCAACA 360 TTGCAAGACA TTGTATTGCA TTTAGAGCCC CAAAATGAAA TTCCGGTTGA CCTTCTAGGT 42 0 CACCAGCAAT TAAGCGACTC AGAGGAAGAA AACGATGAAA TAGATGGAGT TAATCATCAA 480 CATTTACCAG CCCGACGAGC CGAACCACAA CGTCACACAA TGTTGTGTAT GTGTTGTAAG 540 TGTGAAGCCA GAATTGAGCT AGTAGTAGAA AGCTCAGCAG ACGACCTTCG AGCATTCCAG 600 CAGCTGTTTC TGAACACCCT GTCCTTTGTG TGTCCGTGGT GTGCATCCCA GCAGACTAGT 660 GGCCACCATC ACCATCACCA TTAA 684 (2) INFORMATION FOR SEQ ID NO: 19: (i) CHARACTERISTICS OF SEQUENCE : (A) LENGTH: 228 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E7 HPV 18 mutated (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 lie His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Giu Thr Met 100 105 110 Wing Met His Gly Pro Lys Wing Thr Leu Gln Asp He Val Leu His Leu 115 120 125 Glu Pro Gln Asn Glu He Pro Val Asp Leu Leu Gly His Gln Gln Leu 130 135 140 Ser Asp Ser Glu Glu Glu Asn Asp Glu He Asp Gly Val Asn His Gln 145 150 155 160 His Leu Pro Wing Arg Arg Wing Glu Pro Gln Arg His Thr Met Leu Cys 165 170 175 Met Cys Cys Lys Cys Glu Wing Arg He Glu Leu Val Val Glu Ser Ser 180 185 190 Wing Asp Asp Leu Arg Wing Phe Gln Gln Leu Phe Leu Asn Thr Leu Ser 195 200 205 Phe Val Cys Pro Trp Cys Ala Ser Gln Gln Thr Ser Gly His His His 210 215 220 His His His 225 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 837 base pairs (B) TYPE: nucleic acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 - His HPV 18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCGC GCTTTGAGGA TCCAACACGG 360 CGACCCTACA AGCTACCTGA TCTGTGCACG GAACTGAACA CTTCACTGCA AGACATAGAA 420 ATAACCTGTG TATATTGCAA GACAGTATTG GAACTTACAG AGGTATTTGA ATTTGCATTT 480 AAAGATTTAT TTGTGGTGTA TAGAGACAGT ATACCGCATG CTGCATGCCA TAAATGTATA 540 GATTTTTATT CTAGAATTAG AGAATTAAGA CATTATTCAG ACTCTGTGTA TGGAGACACA 600 TTGGAAAAAC TAACTAACAC TGGGTTATAC AATTTATTAA TAAGGTGCCT GCGGTGCCAG 660 AAACCGTTGA ATCCAGCAGA AAAACTTAGA CACCTTAATG AAAAACGACG ATTTCACAAC 720 ATAGCTGGGC ACTATAGAGG CCAGTGCCAT TCGTGCTGCA ACCGAGCACG ACAGGAACGA 780 CTCCAACGAC GCAGAGAAAC ACAAGTAACT AGTGGCCACC ATCACCATCA CCATTAA 837 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 279 amino acids (B) TYPE: amino acid (C) CHAIN STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 - His HPV 18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21 Met Asp Pro Being Ser His Being Being Asn Met Wing Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His ASD His Phe Leu Asp Gly Leu Thr Asp Val Wing Lys Lys Phe 65"70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Arg Phe Glu Asp Pro Thr Arg Pro Tyr Lys Leu Pro Asp Leu 115 120 125 Cys Thr Glu Leu Asn Thr Ser Leu Gln Asp He Glu He Thr Cys Val 130 135 140 Tyr Cys Lys Thr Val Leu Glu Leu Thr Glu Val Phe Glu Phe Ala Phe 145 150 155 160 Lys Asp Leu Phe Val Val Tyr Arg Asp Ser He Pro His Wing Wing Cys 165 170 175 His Lys Cys He Asp Phe Tyr Ser Arg He Arg Glu Leu Arg His Tyr 180 185 190 Ser Asp Ser Val Tyr Gly Asp Thr Leu Glu Lys Leu Thr Asn Thr Gly 195 200 205 Leu Tyr Asn Leu Leu He Arg Cys Leu Arg Cys Gln Lys Pro Leu Asn 210 215 220 Pro Ala Glu Lys Leu Arg His Leu Asn Glu Lys Arg Arg Phe His Asn 225 230 235 240 He Wing Gly His Tyr Arg Gly Gln Cys His Ser Cys Cys Asn Arg Wing 245 250 255 Arg Gln Glu Arg Leu Gln Arg Arg Glu Thr Gln Val Thr Ser Gly 260 265 270 His His His His His His His 275 (2) INFORMATION SEQ ID NO: 22: (!) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1152 base pairs (B) TYPE: nucleic acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 E7 His / HPV18 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 22: ATGGATCCAA GCAGCCATTC ATCAAATATG GCGAATACCC AAATGAAATC AGACAAAATC 60 ATTATTGCTC ACCGTGGTGC TAGCGGTTAT TTACCAGAGC ATACGTTAGA ATCTAAAGCA 120 CTTGCGTTTG CACAACAGGC TGATTATTTA GAGCAAGATT TAGCAATGAC TAAGGATGGT 180 CGTTTAGTGG TTATTCACGA TCACTTTTTA GATGGCTTGA CTGATGTTGC GAAAAAATTC 240 CCACATCGTC ATCGTAAAGA TGGCCGTTAC TATGTCATCG ACTTTACCTT AAAAGAAATT 300 CAAAGTTTAG AAATGACAGA AAACTTTGAA ACCATGGCGC GCTTTGAGGA TCCAACACGG 360 CGACCCTACA AGCTACCTGA TCTGTGCACG GAACTGAACA CTTCACTGCA AGACATAGAA 420 ATAACCTGTG TATATTGCAA GACAGTATTG GAACTTACAG AGGTATTTGA ATTTGCATTT 480 AAAGATTTAT TTGTGGTGTA TAGAGACAGT ATACCGCATG CTGCATGCCA TAAATGTATA 540 GATTTTTATT CTAGAATTAG AGAATTAAGA CATTATTCAG ACTCTGTGTA TGGAGACACA 600 TTGGAAAAAC TAACTAACAC TGGGTTATAC AATTTATTAA TAAGGTGCCT GCGGTGCCAG 660 AAACCGTTGA ATCCAGCAGA AAAACTTAGA CACCTTAATG AAAAACGACG ATTTCACAAC 720 ATAGCTGGGC ACTATAGAGG CCAGTGCCAT TCGTGCTGCA ACCGAGCACG ACAGGAACGA 780 CTCCAACGAC GCAGAGAAAC ACAAGTAATG CATGGACCTA AGGCAACATT GCAAGACATT 840 GTATTGCATT TAGAGCCCCA AAATGAAATT CCGGTTGACC TTCTATGTCA CGAGCAATTA 900 AGCGACTCAG AGGAAGAAAA CGATGAAATA GATGGAGTTA ATCATCAACA TTTACCAGCC 960 CGACGAGCCG AACCACAACG TCACACAATG TTGTGTATGT GTTGTAAGTG TGAAGCCAGA 1020 ATTGAGCTAG TAGTAGAAAG CTCAGCAGAC GACCTTCGAG CATTCCAGCA GCTGTTTCTG 1080 AACACCCTGT CCTTTGTGTG TCCGTGGTGT GCATCCCAGC AGACTAGTGG CCACCATCAC CATCACCATT 1140 AA 1152 (2) INFORMATION FOR SEQ ID NO: 23: (!) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 amino acids (B) TYPE: amino acid (C) STRING STRUCTURE: individual (D) TOPOLOGY: linear Protein D 1/3 E6 E7 His / HPV 18 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: Met Asp Pro Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys 1 5 10 15 Being Asp Lys He He He Wing His Wing Arg Gly Wing Being Gly Tyr Leu Pro 20 25 30 Glu His Thr Leu Glu Ser Lys Wing Leu Wing Phe Wing Gln Gln Wing Asp 35 40 45 Tyr Leu Glu Gln Asp Leu Wing Met Thr Lys Asp Gly Arg Leu Val Val 50 55 60 He His Asp His Phe Leu Asp Gly Leu Thr Asp Val Wing Lys Lys Phe 65 70 75 80 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val He Asp Phe Thr 85 90 95 Leu Lys Glu He Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 100 105 110 Wing Arg Phe Glu Asp Pro Thr Arg Arg Pro Tyr Lys Leu Pro Asp Leu 115 120 125 Cys Thr Glu Leu Asn Thr Ser Leu Gln Asp He Glu He Thr Cys Val 130 135 140 Tyr Cys Lys Thr Val Leu Glu Leu Thr Glu Val Phe Glu Phe Ala Phe 145 150 155 160 Lys Asp Leu Phe Val Val Tyr Arg Asp Ser He Pro His Ala Wing Cys 165 170 175 His Lys Cys He Asp Phe Tyr Ser Arg He Arg Glu Leu Arg His Tyr 180 185 190 Ser Asp Ser Val Tyr Gly Asp Thr Leu Glu Lys Leu Thr Asn Thr Gly 195 200 205 Leu Tyr Asn Leu Leu He Arg Cys Leu Arg Cys Gln Lys Pro Leu Asn 210 215 220 Pro Wing Glu Lys Leu Arg His Leu Asn Glu Lys Arg Arg Phe His Asn 225 230 235 240 He Ala Gly His Tyr Arg Gly Gln Cys His Ser Cys Cys Asn Arg Ala 245 250 255 Arg Gln Glu Arg Leu Gln Arg Arg Glu Thr Gln Val Met His Gly 260 265 270 Pro Lys Wing Thr Leu Gln Asp He Val Leu His Leu Glu Pro Gln Asn 275 280 285 Glu He Pro Val Asp Leu Leu Cys His Glu Gln Leu Ser Asp Ser Glu 290 295 300 Glu Glu Asn Asp Glu He Asp Gly Val Asn His Gln His Leu Pro Wing 30S 310 315 320 Arg Arg Ala Glu Pro Gln Arg His Thr • Met Leu Cys Met Cys Cys Lys 325 330 335 Cys Glu Wing Arg He Glu Leu Val Val Glu Ser Wing Asp Asp Leu 340 345 350 Arg Wing Phe Gln Gln Leu Phe Leu Asn Thr Leu Ser Phe Val Cys Pro 355 360 365 Trp Cys Ala Ser Gln Gln Thr Ser Gly His His His His His His His 370 375 380

Claims (15)

1. A composition comprising an E6 or E7 protein or an E6 / E7 fusion protein from HPV optionally linked to an immunological fusion pattern, and an immunomodulatory CpG oligonucleotide.

2. A composition according to claim 1, wherein the fusion pattern is selected from the group of: protein D or a fragment thereof from Haemophilus n nfluenzae B, lipoprotein D or fragment thereof from Haemophilus influenzae B, NS1 or its fragment from the Influenzae virus, and LYTA or fragment thereof from Streptococcus Pneumoniae.

3. A composition according to claim 1 or 2, wherein the E6 or E7 proteins are derived from HPV16 or HPV18.

4. A composition according to claim 1, 2 or 3, wherein the E7 protein is mutated.

5. A composition according to claim 1, 2 or 3, wherein the E6 protein is mutated.

6. A composition according to any of claims 1 to 5 further comprising a histidine tag of at least 4 histidine residues.

7. A composition according to the present invention comprising an additional HPV antigen.

8. A composition according to the present invention wherein the immunomodulatory CpG oligonucleotide comprises a hexamer motif: purine purine cytosine guain pyrimidine pyrimidine.

9. A composition according to the present, wherein the immunomodulatory CpG oligonucleotide has two or more CpG motifs.

10. - A composition according to the present, wherein the CpG oligonucleotide contains a link between phosphorothioate nucleotides.

11. A composition according to the present, wherein the CpG oligonucleotide is selected from the group consisting of: OLIGO 1: TCC ATG ACG TTC CTG ACG TT OLIGO 2: TCT CCC AGC GTG CGC CAT OLIGO 3: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG

12. A composition according to the present, for use in medicine.

13. A method for inducing an immune response in a patient to an HPV antigen, comprising administering a safe and effective amount of a composition according to the present invention.

14. A method for preventing or treating HPV-induced tumors in a patient, comprising administering a safe and effective amount of a composition according to the present invention.

15. A method for preparing a composition according to the present invention, comprising mixing an E6, E7 or E6 / E7 fusion protein optionally linked to an immunological fusion pattern, and an immunomodulatory CpG oligonucleotide.